Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $253.98 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Annexon Inc had its IPO on 2020-07-24 under the ticker symbol ANNX.
The company operates in the Healthcare sector and Biotechnology industry. Annexon Inc has a staff strength of 0 employees.
Shares of Annexon Inc opened at $3 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $2.92 - $3.16, and closed at $2.98.
This is a -0.67% slip from the previous day's closing price.
A total volume of 1,372,983 shares were traded at the close of the day’s session.
In the last one week, shares of Annexon Inc have slipped by -42.36%.
Annexon Inc's Key Ratios
Annexon Inc has a market cap of $253.98 million, indicating a price to book ratio of 0.9979 and a price to sales ratio of 0.
In the last 12-months Annexon Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-143497664. The EBITDA ratio measures Annexon Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Annexon Inc’s operating margin was 0% while its return on assets stood at -31.81% with a return of equity of -61.3%.
In Q4, Annexon Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Annexon Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.74 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Annexon Inc’s profitability.
Annexon Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.1681. Its price to sales ratio in the trailing 12-months stood at 0.
Annexon Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $285.10 million
- Total Liabilities
- $22.36 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Annexon Inc ended 2023 with $285.10 million in total assets and $0 in total liabilities. Its intangible assets were valued at $285.10 million while shareholder equity stood at $231.19 million.
Annexon Inc ended 2023 with $0 in deferred long-term liabilities, $22.36 million in other current liabilities, 48000.00 in common stock, $-438262000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $140.02 million and cash and short-term investments were $242.66 million. The company’s total short-term debt was $1,316,000 while long-term debt stood at $0.
Annexon Inc’s total current assets stands at $248.10 million while long-term investments were $0 and short-term investments were $102.64 million. Its net receivables were $0 compared to accounts payable of $7.42 million and inventory worth $0.
In 2023, Annexon Inc's operating cash flow was $-43615000.00 while its capital expenditure stood at $282000.
Comparatively, Annexon Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Annexon Inc stock is currently trading at $2.98 per share. It touched a 52-week high of $7.65 and a 52-week low of $7.65. Analysts tracking the stock have a 12-month average target price of $18.71.
Its 50-day moving average was $4.74 and 200-day moving average was $5.43 The short ratio stood at 2.53 indicating a short percent outstanding of 0%.
Around 253.3% of the company’s stock are held by insiders while 11021.1% are held by institutions.
Frequently Asked Questions About Annexon Inc
Similar Industry Stocks (Biotechnology)
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company’s C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington’s disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.